CRVS Stock Price, Corvus Pharmaceuticals Quote, Chart

Market Summary

USD2.21-0.05

Market Closed

-2.21%

CRVS Alerts

Point72 Asset Management, L.P. reported owning 9.9% of CRVS [2024-05-09]

2 major insider buys recently.

CRVS Stock Price

View Fullscreen

CRVS RSI Chart

CRVS Valuation

Market Cap

110.8M

Price/Earnings (Trailing)

-4.46

Price/Sales (Trailing)

1.4K

Price/Free Cashflow

-5.27

CRVS Price/Sales (Trailing)

CRVS Profitability

Return on Equity

-74.5%

Return on Assets

-62.01%

Free Cashflow Yield

-18.96%

CRVS Fundamentals

CRVS Revenue

Revenue (TTM)

78.0K

Rev. Growth (Yr)

-85.14%

Rev. Growth (Qtr)

-43.59%

CRVS Earnings

Earnings (TTM)

-24.9M

Earnings Growth (Yr)

27.59%

Earnings Growth (Qtr)

14.31%

Breaking Down CRVS Revenue

Last 7 days

35.1%

Last 30 days

48.4%

Last 90 days

1.8%

Trailing 12 Months

-12.7%

How does CRVS drawdown profile look like?

CRVS Financial Health

Current Ratio

3.4

CRVS Investor Care

Shares Dilution (1Y)

5.30%

Diluted EPS (TTM)

-0.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	497.0K	0	287.5K	78.0K
2022	323.0K	411.0K	499.0K	587.0K
2021	0	0	0	235.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Corvus Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	jones william benton	bought	34,624	1.7312	20,000	see remarks
May 06, 2024	miller richard a md	bought	1,000,000	1.7312	577,634	president and ceo
May 15, 2023	grais linda	bought	24,500	2.45	10,000	-
Dec 20, 2022	jones william benton	bought	15,800	0.79	20,000	see remarks
Dec 14, 2022	miller richard a md	bought	7,812	0.7812	10,000	president and ceo
Dec 14, 2022	lea leiv	bought	3,364	0.841	4,000	chief financial officer
Dec 13, 2022	miller richard a md	bought	37,015	0.7403	50,000	president and ceo
Dec 13, 2022	lea leiv	bought	22,275	0.7425	30,000	chief financial officer
Sep 28, 2022	miller richard a md	bought	19,070	0.7628	25,000	president and ceo
Sep 20, 2022	miller richard a md	bought	16,253	0.812662	20,000	president and ceo

Which funds bought or sold CRVS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	XTX Topco Ltd	sold off	-100	-41,210	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	3.16	27,484	661,894	-%
May 13, 2024	UBS Group AG	reduced	-30.16	-3,463	8,329	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	8.44	100,000	1,134,000	-%
May 13, 2024	FMR LLC	new	-	30.00	30.00	-%
May 13, 2024	NATIXIS	sold off	-100	-1,408	-	-%
May 10, 2024	JPMORGAN CHASE & CO	added	7,679	92,832	94,027	-%
May 10, 2024	GROUP ONE TRADING, L.P.	reduced	-87.44	-56,334	8,195	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	1.92	14.00	472	-%
May 10, 2024	BlackRock Inc.	added	0.47	14,731	930,901	-%

Are Funds Buying or Selling CRVS?

Are funds buying CRVS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRVS

No. of Funds

CRVS Alerts

Point72 Asset Management, L.P. reported owning 9.9% of CRVS [2024-05-09]
2 major insider buys recently.

Unveiling Corvus Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	samlyn capital, llc	9.99%	6,267,984	SC 13G/A
May 09, 2024	point72 asset management, l.p.	9.9%	17,050,384	SC 13G
May 08, 2024	orbimed advisors llc	11.1%	6,943,654	SC 13D/A
Feb 14, 2024	samlyn capital, llc	5.1%	2,496,259	SC 13G
Feb 13, 2024	miller richard a md	7.19%	3,684,010	SC 13G/A
Feb 14, 2023	tang capital partners lp	0.0%	0	SC 13G/A
Feb 13, 2023	chi advisors llc	5.12%	2,384,402	SC 13G
Feb 10, 2023	miller richard a md	6.45%	3,105,121	SC 13G/A
Jan 30, 2023	integrated core strategies (us) llc	4.1%	1,888,732	SC 13G/A
Feb 14, 2022	miller richard a md	5.45%	2,607,148	SC 13G/A

Recent SEC filings of Corvus Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 13, 2024	SC 13G/A	Major Ownership Report
May 09, 2024	SC 13G	Major Ownership Report
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 08, 2024	SC 13D/A	13D - Major Acquisition
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Corvus Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.91	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.98	9.54	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.39	14.63	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.02	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Corvus Pharmaceuticals Inc News

Latest updates

Corvus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-43.6%	22,000	39,000	56,000	148,000	147,000	146,000	146,000	120,000	94,000
Operating Expenses	1.6%	5,651,000	5,560,000	6,574,000	5,666,000	12,473,000	7,013,000	7,413,000	6,810,000	9,047,000
S&GA Expenses	3.6%	1,652,000	1,595,000	1,980,000	1,586,000	2,108,000	2,090,000	2,313,000	2,022,000	2,056,000
R&D Expenses	0.9%	3,999,000	3,965,000	4,594,000	4,080,000	10,365,000	4,923,000	5,100,000	4,788,000	6,991,000
EBITDA Margin	-	-	-	-	-	-	-80.41	-83.01	-182	-
EBT Margin	-	-	-	-	-	-	-81.13	-83.80	-184	-
Net Income	-10.9%	-6,653,000	-6,000,000	-7,873,000	-9,816,000	-14,831,000	-8,363,000	-8,297,000	-9,236,000	-10,673,000
Net Income Margin	-230.0%	-346	-105	-82.26	-70.37	-81.62	-88.98	-123	-184	-
Free Cashflow	4.9%	-5,167,000	-5,434,000	-8,145,000	-7,524,000	-7,194,000	-6,123,000	-6,424,000	-6,841,000	-8,425,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.0%	40.00	46.00	52.00	58.00	58.00	68.00	80.00	93.00	101	109	119	109	109	86.00	56.00	64.00	74.00	84.00	92.00	103	112
Current Assets	-18.3%	23.00	28.00	33.00	38.00	36.00	44.00	51.00	59.00	64.00	71.00	79.00	69.00	69.00	45.00	53.00	61.00	70.00	79.00	88.00	98.00	107
Cash Equivalents	-40.9%	7.00	13.00	20.00	8.00	10.00	13.00	25.00	28.00	31.00	63.00	72.00	59.00	45.00	16.00	23.00	21.00	23.00	5.00	9.00	30.00	39.00
Net PPE	-9.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
Liabilities	-2.2%	7.00	7.00	8.00	9.00	9.00	12.00	16.00	12.00	12.00	12.00	14.00	13.00	15.00	13.00	14.00	13.00	14.00	13.00	12.00	13.00	12.00
Current Liabilities	-2.2%	7.00	7.00	7.00	8.00	8.00	11.00	14.00	10.00	9.00	10.00	11.00	12.00	14.00	12.00	12.00	12.00	12.00	10.00	10.00	11.00	9.00
Shareholder's Equity	-13.8%	33.00	39.00	44.00	49.00	49.00	56.00	65.00	80.00	90.00	97.00	105	96.00	94.00	72.00	42.00	51.00	60.00	71.00	80.00	90.00	101
Retained Earnings	-1.7%	-340	-334	-328	-322	-315	-307	-297	-283	-274	-266	-257	-246	-234	-223	-250	-240	-230	-217	-206	-195	-182
Additional Paid-In Capital	0.2%	375	374	374	373	365	364	364	363	362	362	361	341	329	295	293	291	290	288	286	285	283
Shares Outstanding	0%	49.00	49.00	49.00	49.00	47.00	47.00	47.00	47.00	47.00	42.00	44.00	38.00	35.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	84.00	-	-	-	34.00	-	-	-	65.00	-	-	-	44.00	-	-	-	66.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	0.2%	-5,157	-5,167	-5,434	-5,223	-8,111	-7,524	-6,929	-6,123	-6,424	-6,841	-8,425	-12,647	-8,787	-8,207	-7,732	-9,486	-9,353	-8,510	-10,607	-9,214	-8,990
Share Based Compensation	20.5%	689	572	546	537	492	620	658	675	739	738	1,096	1,173	1,225	1,236	1,283	1,383	1,845	1,748	1,749	1,898	1,953
Cashflow From Investing	99.7%	-7.00	-2,318	17,546	-4,289	4,602	-3,882	3,040	3,140	-25,574	-1,999	3,471	15,242	4,846	463	9,939	6,670	27,697	4,595	-10,525	416	8,769
Cashflow From Financing	-	-	-	335	7,516	4.00	-	-	-	-	18.00	18,334	11,216	32,590	1,223	64.00	-	-	2.00	16.00	5.00	1.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRVS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 4,075	$ 4,594
General and administrative	2,178	1,980
Total operating expenses	6,253	6,574
Loss from operations	(6,253)	(6,574)
Interest income and other expense, net	316	376
Sublease income - related party		56
Loss before equity method investment	(5,937)	(6,142)
Income (loss) from equity method investment	236	(1,731)
Net loss	$ (5,701)	$ (7,873)
Net loss per share, basic	$ (0.12)	$ (0.17)
Net loss per share, diluted	$ (0.12)	$ (0.17)
Shares used to compute net loss per share, basic	49,038,582	46,556,178
Shares used to compute net loss per share, diluted	49,038,582	46,556,178
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	$ (15)	$ 41
Cumulative foreign currency translation adjustment	(293)	88
Comprehensive loss	$ (6,009)	$ (7,744)

CRVS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,456	$ 12,620
Marketable securities	14,672	14,529
Accounts receivable - related party	26	26
Prepaid and other current assets	697	781
Total current assets	22,851	27,956
Property and equipment, net	213	236
Operating lease right-of-use asset	865	1,149
Investment in Angel Pharmaceuticals	16,066	16,123
Other assets	89	89
Total assets	40,084	45,553
Current liabilities:
Accounts payable	1,609	1,525
Operating lease liability	1,040	1,374
Accrued and other liabilities	4,071	3,970
Total current liabilities	6,720	6,869
Total liabilities	6,720	6,869
Stockholders' equity:
Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,038,582 shares issued and outstanding at March 31, 2024 and December 31, 2023	5	5
Additional paid-in capital	375,052	374,363
Accumulated other comprehensive loss	(1,275)	(967)
Accumulated deficit	(340,418)	(334,717)
Total stockholders' equity	33,364	38,684
Total liabilities and stockholders' equity	$ 40,084	$ 45,553

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CEO	Dr. Richard A. Miller M.D.
WEBSITE	corvuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	29

Corvus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Corvus Pharmaceuticals Inc? What does CRVS stand for in stocks?

CRVS is the stock ticker symbol of Corvus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Corvus Pharmaceuticals Inc (CRVS)?

As of Tue May 14 2024, market cap of Corvus Pharmaceuticals Inc is 110.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRVS stock?

You can check CRVS's fair value in chart for subscribers.

What is the fair value of CRVS stock?

You can check CRVS's fair value in chart for subscribers. The fair value of Corvus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Corvus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRVS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Corvus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CRVS is over valued or under valued. Whether Corvus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Corvus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRVS.

What is Corvus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, CRVS's PE ratio (Price to Earnings) is -4.46 and Price to Sales (PS) ratio is 1.42 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRVS PE ratio will change depending on the future growth rate expectations of investors.